Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) EPS (Weighted Average and Diluted) (2016 - 2025)

United Therapeutics (UTHR) has disclosed EPS (Weighted Average and Diluted) for 17 consecutive years, with $7.69 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 23.83% to $7.69 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $27.89 through Dec 2025, up 13.28% year-over-year, with the annual reading at $27.86 for FY2025, 13.07% up from the prior year.
  • EPS (Weighted Average and Diluted) hit $7.69 in Q4 2025 for United Therapeutics, up from $7.16 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $7.69 in Q4 2025 to a low of $0.61 in Q1 2021.
  • Historically, EPS (Weighted Average and Diluted) has averaged $4.87 across 5 years, with a median of $5.14 in 2022.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): tumbled 80.45% in 2021 and later soared 724.59% in 2022.
  • Year by year, EPS (Weighted Average and Diluted) stood at $2.34 in 2021, then increased by 13.25% to $2.65 in 2022, then soared by 63.4% to $4.33 in 2023, then skyrocketed by 43.42% to $6.21 in 2024, then increased by 23.83% to $7.69 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for UTHR at $7.69 in Q4 2025, $7.16 in Q3 2025, and $6.41 in Q2 2025.